| Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20493430 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: In a previous study involving 18 hypertensive patients with type 2 diabetes mellitus, we found that replacement of valsartan and candesartan by telmisartan significantly improved insulin sensitivity and significantly increased serum adiponectin levels in the patients. We investigated the effects of 3 angiotensin II type 1 receptor blockers (ARBs)-telmisartan, candesartan, and valsartan-on metabolic parameters in hypertensive patients with type 2 diabetes. METHODS: A total of 308 hypertensive patients with diabetes were enrolled in our multicentre, randomized, open-label study. The patients received 40 mg telmisartan, 8 mg candesartan, or 80 mg valsartan for 3 months, and the data of 227 patients (telmisartan: n=74, candesartan: n=79, and valsartan: n=74) were analysed. RESULTS: The systolic and diastolic blood pressures significantly decreased in all the groups at the end of the study; the decrease was comparable among the 3 groups. The changes in fasting plasma glucose, fasting insulin, glycated haemoglobin (HbA1c), total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, adiponectin, free fatty acids, high-sensitivity C-reactive protein (hs-CRP), and plasminogen activator inhibitor-1 (PAI-1) were comparable between the 3 groups. Telmisartan and candesartan administration tended to lower urinary albumin excretion. CONCLUSIONS: Low dose telmisartan had a neutral effect on metabolic dysfunction in hypertensive patients with type 2 diabetes; the effect produced by 40 mg telmisartan was comparable with that of 8 mg candesartan and 80 mg valsartan. Failure to detect metabolic differences among the various ARB treatments could have been due to the low statistical power of the study design. |
| | |
Authors:
|
Nobuaki Ozaki; Yoshio Nomura; Hiroshi Sobajima; Kunikazu Kondo; Yutaka Oiso |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-02-18 |
Journal Detail:
|
Title: European journal of internal medicine Volume: 21 ISSN: 1879-0828 ISO Abbreviation: Eur. J. Intern. Med. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-24 Completed Date: 2010-08-23 Revised Date: 2012-04-09 |
Medline Journal Info:
|
Nlm Unique ID: 9003220 Medline TA: Eur J Intern Med Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 236-9 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. |
Affiliation:
|
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Japan. n-ozaki@med.nagoya-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adiponectin
/
blood Aged Angiotensin II Type 1 Receptor Blockers / administration & dosage* Benzimidazoles / administration & dosage* Benzoates / administration & dosage* Blood Glucose / drug effects Blood Pressure / drug effects C-Reactive Protein / metabolism Diabetes Mellitus, Type 2 / complications, drug therapy*, metabolism Dose-Response Relationship, Drug Female Hemoglobin A, Glycosylated / metabolism Humans Hypertension / complications, drug therapy*, metabolism Insulin Resistance Lipids / blood Male Middle Aged Tetrazoles / administration & dosage* Treatment Outcome Valine / administration & dosage, analogs & derivatives* |
| Chemical | |
Reg. No./Substance:
|
0/ADIPOQ protein, human; 0/Adiponectin; 0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Lipids; 0/Tetrazoles; 137862-53-4/valsartan; 139481-59-7/candesartan; 144701-48-4/telmisartan; 7004-03-7/Valine; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Numbers needed to hospitalize-Risks and benefits of admission in the new decade.
Next Document: Drug-induced taste disorders.